Company Announcement AbbVie Inc. files complaint against Genmab in the U.S. District Court for the Western District of Washington (Seattle) ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

Discover the top-performing Dividend Kings of 2025, outperforming the S&P 500 by 4.57%. Click here to explore more promising ...

Proficio Capital Partners just added 2,230 shares of AbbVie, giving its portfolio a pharma-flavored boost worth $1.18 million ...

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...

A migraine attack is more than a headache. It can derail your entire day.

Shares of AbbVie were recently trading for $212 apiece, and the company's total annual dividend amount (paid out over four ...

AbbVie’s stock dipped 0.29% to close at $213.85, a minor move compared to the S&P 500's steeper 1.07% drop. Despite this ...

With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

AbbVie (ABBV) closed the most recent trading day at $213.85, moving -0.29% from the previous trading session. The stock's performance was ahead of the S&P 500's daily loss of 1.07%. At the same time, ...